Pfizer to divide firm into three businesses

Pfizer has unveiled plans to restructure the company into three business units, separating biosimilars, generics and OTC medicines. Biosimilars will be housed in the US firm’s ‘Innovative Medicines’ division, alongside a new hospital business unit for anti-infectives and sterile injectables; an ‘Established Medicines’ segment will incorporate “certain generics” with Pfizer’s off-patent solid oral-dose legacy brands, “operating with substantial autonomy within Pfizer”; and a ‘Consumer Healthcare’ division will include the company’s OTC medicines. The changes will come into effect at the start of 2019.

Pfizer has unveiled plans to restructure the company into three business units, separating biosimilars, generics and OTC medicines. Biosimilars will be housed in the US firm’s ‘Innovative Medicines’ division, alongside a new hospital business unit for anti-infectives and sterile injectables; an ‘Established Medicines’ segment will incorporate “certain generics” with Pfizer’s off-patent solid oral-dose legacy brands, “operating with substantial autonomy within Pfizer”; and a ‘Consumer Healthcare’ division will include the company’s OTC medicines. The changes will come into effect at the start of 2019.

“This new structure represents a natural evolution of these businesses, given the ongoing strength of our in-market products and our...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin